Skip to main content

Barclays Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Tipranks - Tipranks - Thu Feb 26, 4:04AM CST

Barclays analyst Eliana Merle maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $80.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Merle is a 4-star analyst with an average return of 4.4% and a 43.78% success rate. Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BridgeBio Pharma, and Alnylam Pharma.

In addition to Barclays, BioMarin Pharmaceutical also received a Buy from TipRanks – Anthropic’s Anthropic Biotechnology in a report issued yesterday. However, on the same day, William Blair maintained a Hold rating on BioMarin Pharmaceutical (NASDAQ: BMRN).

See Insiders’ Hot Stocks on TipRanks >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).